In this episode, we discuss the pharmacology of the renin-angiotensin-aldosterone system and review the evidence for combining ACE-Is, ARBs, and/or DRIs.

In this episode, we discuss the 2005 ATS/IDSA Healthcare-Associated, Hospital-Acquired, and Ventilator-Associated Pneumonia Guidelines (HCAP, HAP, VAP).

In this episode, we discuss the 2007 ATS/IDSA Community-Acquired Pneumonia (CAP) guidelines.

In this episode, we discuss updates to the GOLD guidelines for COPD and review the newer agents for COPD including roflumilast (Daliresp), indacaterol (Arcapta Neohaler), aclidinium (Tudorza Pressair), umeclidinium/vilanterol (Anoro Ellipta), and fluticasone/vilanterol (Breo Ellipta).

In this episode, we discuss smoking cessation, including nicotine replacement therapy, bupropion (Zyban), and varenicline (Chantix).

In this episode, we discuss the P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) and the role of dual antiplatelet therapy (DAPT) and triple oral antithrombotic therapy (TOAT).

In this episode, we discuss the new drug class of Novel Oral Anticoagulants (NOACs), which include dabigatran (Pradaxa), rivaroxaban (Xarelto), and apixaban (Eliquis).

In this episode, we discuss the new JNC 8 guidelines and how these guidelines differ from other hypertension guidelines released in 2013-2014.

In this episode, we discuss the new, rebranded podcat (HelixTalk) and review the new ACC/AHA 2013 lipid guidelines.

In this session of the RFUMS Top 200 Drugs Podcast, we discuss women’s health: conjugated estrogens, ethinyl estradiol, norethindrone, norgestrel, etonogestrel, medroxyprogesterone, raloxifene, tamoxifen, miconazole, Midol, phenazopyridine.